Skip to main content

Publications

Global HIV control: is the glass half empty or half full?

Global HIV control: is the glass half empty or half full?

The massive scale-up of HIV treatment and prevention over the past two decades has resulted in important reductions in new infections and mortality globally. Reduction in HIV incidence, however, has been unequal, with worsening epidemics in regions where the reach and scale of HIV control programmes have been insufficient.
August 2, 2023
PEPFAR at 20 – A Game-Changing Impact on HIV in Africa

PEPFAR at 20 – A Game-Changing Impact on HIV in Africa

Interview with Jean Nachega on PEPFAR’s achievements and remaining challenges in HIV prevention and treatment in sub-Saharan Africa.
July 7, 2023
Oral Fluvoxamine With Inhaled Budesonide for Treatment of Early-Onset COVID-19 : A Randomized Platform Trial

Oral Fluvoxamine With Inhaled Budesonide for Treatment of Early-Onset COVID-19 : A Randomized Platform Trial

Previous trials have demonstrated the effects of fluvoxamine alone and inhaled budesonide alone for prevention of disease progression among outpatients with COVID-19.
May 23, 2023
Long-acting antiretrovirals and HIV treatment adherence

Long-acting antiretrovirals and HIV treatment adherence

Intramuscular injection of long-acting cabotegravir and rilpivirine is a novel, long-acting antiretroviral therapy (ART) combination approved for use as a fully suppressive regimen for people living with HIV.
May 2, 2023
Long-acting antiretrovirals and HIV treatment adherence

The importance of appropriate selection of clinical endpoints in outpatient COVID-19 clinical trials

Intramuscular injection of long-acting cabotegravir and rilpivirine is a novel, long-acting antiretroviral therapy (ART) combination approved for use as a fully suppressive regimen for people living with HIV.
April 23, 2023
The effect of group support psychotherapy on adherence to anti-retroviral therapy and viral suppression among HIV positive young people: Study protocol for a pilot randomized controlled trial

The effect of group support psychotherapy on adherence to anti-retroviral therapy and viral suppression among HIV positive young people: Study protocol for a pilot randomized controlled trial

Several studies have demonstrated an association between psychological risk factors and HIV disease progression. However, there is limited information on the use of psychological interventions to improve HIV treatment outcomes in young people living with HIV.
April 5, 2023
Pegylated Interferon Lambda for Covid-19. Reply

Early Treatment with Pegylated Interferon Lambda for Covid-19

The efficacy of a single dose of pegylated interferon lambda in preventing clinical events among outpatients with acute symptomatic coronavirus disease 2019 (Covid-19) is unclear.
February 10, 2023
Estimating HIV Incidence In Sub-Saharan Africa

Estimating HIV Incidence In Sub-Saharan Africa

Over the past 3 years, the COVID-19 pandemic has affected health systems in sub-Saharan Africa that were already highly burdened by other infectious diseases such as HIV. Although substantial progress has been made in reducing new HIV infections globally, Africa is still disproportionately affected, accounting for two-thirds of all people living with HIV. 2 The global target to achieve 95% of HIV testing, treatment, and controlled viral suppression by 2030 requires nuanced and innovative ways of understanding HIV transmission dynamics at the national, regional, and subregional levels, and availability of new treatments and preventive strategies on a broad scale.
January 23, 2023
Advancing Detection And Response Capacities For Emerging And Re-Emerging Pathogens In Africa

Advancing Detection And Response Capacities For Emerging And Re-Emerging Pathogens In Africa

Recurrent disease outbreaks caused by a range of emerging and resurging pathogens over the past decade reveal major gaps in public health preparedness, detection, and response systems in Africa. Underlying causes of recurrent disease outbreaks include inadequacies in the detection of new infectious disease outbreaks in the community, rapid pathogen identification, and proactive surveillance systems.
December 21, 2022
Advancing Pathogen Detection and Tracking in Africa

Advancing Pathogen Detection and Tracking in Africa

Recurrent disease outbreaks caused by a range of emerging and resurging pathogens over the past decade reveal major gaps in public health preparedness, detection, and response systems in Africa.
December 20, 2022
Resilient clinical trial infrastructure in response to the COVID-19 pandemic

Resilient clinical trial infrastructure in response to the COVID-19 pandemic

In 2020, clinical trial researchers developed protocols to evaluate the safety and effectiveness of potential treatments for COVID-19. Despite more than 3,000 trials registered, few have generated findings, with the exception of smaller randomized controlled trials.
September 22, 2022
Interferon treatments for SARS-CoV-2: Challenges and opportunities

Interferon treatments for SARS-CoV-2: Challenges and opportunities

Interferon (IFN) therapies are used to treat a variety of infections and diseases and could be used to treat SARS-CoV-2. However, optimal use and timing of IFN therapy to treat SARS-CoV-2 is not well documented. We aimed to synthesize available evidence to understand whether interferon therapy should be recommended for treatment compared to a placebo or standard of care in adult patients.
April 21, 2022
Effect of early treatment with ivermectin among patients with COVID-19

Effect of early treatment with ivermectin among patients with COVID-19

The efficacy of ivermectin in preventing hospitalization or extended observation in an emergency setting among outpatients with acutely symptomatic coronavirus disease 2019 (Covid-19), the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is unclear.
March 20, 2022
Moving forward in clinical research with master protocols

Moving forward in clinical research with master protocols

With billions of dollars in research and development funding continuing to be invested, COVID-19 has become into a singular focus for the scientific community. However, the collective response from the scientific communities has seen poor return on investment, particularly for therapeutic research for COVID-19, revealing the existing weaknesses and inefficiencies of the clinical trial enterprise.
May 14, 2021
How COVID-19 has fundamentally changed clinical research in global health

How COVID-19 has fundamentally changed clinical research in global health

The COVID-19 pandemic has put enormous pressure on the medical research community to move quickly, yet many clinical trials have been arguably inefficient with questionable methdological quality. The pandemic has highlighted the need for more collaboration and coordination, with large scale clinical trials and master protocols that can inform policy and public health practices.
May 1, 2021

Search

Publication Month

Publication Year